$216 Million is the total value of Parkman Healthcare Partners LLC's 66 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TELA | Exit | TELA BIO INC | $0 | – | -25,000 | -100.0% | -0.09% | – |
| PHAS | Exit | PHASEBIO PHARMACEUTICALS INC | $0 | – | -91,091 | -100.0% | -0.16% | – |
| XNCR | Exit | XENCOR INC | $0 | – | -25,000 | -100.0% | -0.25% | – |
| CDMO | Exit | AVID BIOSERVICES INC | $0 | – | -140,523 | -100.0% | -0.31% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO L | $0 | – | -20,000 | -100.0% | -0.31% | – |
| MYOV | Exit | MYOVANT SCIENCES LTD | $0 | – | -99,413 | -100.0% | -0.44% | – |
| FTSV | Exit | FORTY SEVEN INC | $0 | – | -40,000 | -100.0% | -0.46% | – |
| GH | Exit | GUARDANT HEALTH INC | $0 | – | -30,250 | -100.0% | -0.68% | – |
| BLFS | Exit | BIOLIFE SOLUTIONS INC | $0 | – | -166,000 | -100.0% | -0.78% | – |
| KIDS | Exit | ORTHOPEDIATRICS CORP | $0 | – | -60,000 | -100.0% | -0.81% | – |
| FOMX | Exit | FOAMIX PHARMACEUTICALS LTD | $0 | – | -932,141 | -100.0% | -0.90% | – |
| ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -23,004 | -100.0% | -0.92% | – |
| RGNX | Exit | REGENXBIO INC | $0 | – | -85,000 | -100.0% | -1.00% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INC | $0 | – | -275,505 | -100.0% | -1.90% | – |
| TFX | Exit | TELEFLEX INC | $0 | – | -18,600 | -100.0% | -2.02% | – |
| XBI | Exit | SPDR SERIES TRUSTput | $0 | – | -75,000 | -100.0% | -2.06% | – |
| TNDM | Exit | TANDEM DIABETES CARE INC | $0 | – | -134,959 | -100.0% | -2.32% | – |
| BSX | Exit | BOSTON SCIENTIFIC CORP | $0 | – | -275,000 | -100.0% | -3.59% | – |
| ZBH | Exit | ZIMMER BIOMET HLDGS INC | $0 | – | -95,000 | -100.0% | -4.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DEXCOM INC | 16 | Q3 2023 | 6.3% |
| ACLARIS THERAPEUTICS INC | 16 | Q3 2023 | 10.0% |
| XENON PHARMACEUTICALS INC | 16 | Q3 2023 | 3.3% |
| NATERA INC | 16 | Q3 2023 | 3.4% |
| AVID BIOSERVICES INC | 15 | Q3 2023 | 2.9% |
| SCHRODINGER INC | 15 | Q3 2023 | 4.2% |
| REPRO MED SYS INC | 15 | Q2 2023 | 2.0% |
| MANNKIND CORP | 15 | Q3 2023 | 1.6% |
| IQVIA HLDGS INC | 14 | Q1 2023 | 4.6% |
| INSULET CORP | 14 | Q3 2023 | 2.9% |
View Parkman Healthcare Partners LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PLUS THERAPEUTICS, INC. | February 13, 2023 | 583,467 | 1.7% |
View Parkman Healthcare Partners LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-13 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Parkman Healthcare Partners LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.